Birgit Zucker

Summary

Country: Germany

Publications

  1. ncbi request reprint Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective
    Zhihua Qiu
    Massachusetts General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA 02129, USA
    J Biol Chem 281:16672-80. 2006
  2. ncbi request reprint Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1
    Birgit Zucker
    Department of Neurology, MassGeneral Institute for Neurodegenerative Diseases, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    Hum Mol Genet 14:179-89. 2005
  3. ncbi request reprint Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation
    Jonathan H Fox
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, USA
    J Neurochem 91:413-22. 2004
  4. ncbi request reprint Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice
    Robert J Ferrante
    Geriatric Research Education and Clinical Center, Bedford Veterans Affairs Medical Center, Bedford, Massachusetts 01730, USA
    J Neurosci 23:9418-27. 2003
  5. ncbi request reprint Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease
    Birgit Zucker
    Department of Neurology, University Hospital Freiburg, Breisacherstrasse 64, 79106 Freiburg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 370:131-9. 2004

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective
    Zhihua Qiu
    Massachusetts General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA 02129, USA
    J Biol Chem 281:16672-80. 2006
    ..Our data suggest that enhancement of transcription factor Sp1 contributes to the pathology of HD and demonstrates that its suppression is beneficial...
  2. ncbi request reprint Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1
    Birgit Zucker
    Department of Neurology, MassGeneral Institute for Neurodegenerative Diseases, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    Hum Mol Genet 14:179-89. 2005
    ....
  3. ncbi request reprint Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation
    Jonathan H Fox
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, USA
    J Neurochem 91:413-22. 2004
    ..We suggest that cystamine's neuroprotective effect in HD transgenic mice results from pleiotropic effects that include transglutaminase inhibition and antioxidant activity...
  4. ncbi request reprint Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice
    Robert J Ferrante
    Geriatric Research Education and Clinical Center, Bedford Veterans Affairs Medical Center, Bedford, Massachusetts 01730, USA
    J Neurosci 23:9418-27. 2003
    ....
  5. ncbi request reprint Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease
    Birgit Zucker
    Department of Neurology, University Hospital Freiburg, Breisacherstrasse 64, 79106 Freiburg, Germany
    Naunyn Schmiedebergs Arch Pharmacol 370:131-9. 2004
    ..The pharmacokinetics of GBP-L yielded a mean plasma concentration near the EC50 of GBP-L to open mitochondrial ATP-dependent K+ channels. These findings support the role of GBP-L as a novel neuroprotective substance in vivo...